Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
Human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-associated virus (LAV) is a a newly discovered lymphotropic retrovirus that is cytopathic for helper/inducer T cells in vitro. This virus is the etiologic agent of the acquired immunodeficiency syndrome and related diseases. In the current study, we tested the capacity of purine and pyrimidine nucleoside derivatives to inhibit the infectivity and cytopathic effect of human T-lymphotropic virus type III in vitro. With the ribose moiety of the molecule in a 2',3'-dideoxy configuration, every purine (adenosine, guanosine, and inosine) and pyrimidine (cytidine and thymidine) nucleoside tested suppressed the virus, although the thymidine derivative seemed to have substantially less activity in our system than the others. In general, we observed essentially complete suppression of the virus at doses that were lower by a factor of 10 to 20 than those needed to inhibit the proliferation of the target T cells and the immune reactivity of normal T cells in vitro. An analysis of five adenosine congeners, which differed only in the sugar moiety, revealed that reduction (an absence of hydroxyl determinants) at both the 2' and 3' carbons of the ribose was necessary for an anti-viral effect, and an additional reduction at the 5' carbon nullified the anti-viral activity. These observations may be of value in developing a new class of experimental drugs for the therapy of human T-lymphotropic virus type III infections.
D000998:Antiviral Agents / Q000494:pharmacology*; D002236:Carbohydrate Conformation; D002455:Cell Division; D003588:Cytopathogenic Effect, Viral; D017977:Deltaretrovirus / Q000187:drug effects* / Q000472:pathogenicity; D003839:Deoxyadenosines / Q000031:analogs & derivatives / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D003853:Deoxyribonucleosides / Q000494:pharmacology*; D016048:Dideoxyadenosine; D015224:Dideoxynucleosides; D015683:Gene Products, gag; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008934:Mitogens / Q000494:pharmacology; D012191:Retroviridae Proteins / Q000096:biosynthesis; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000382:microbiology; D013936:Thymidine / Q000031:analogs & derivatives / Q000494:pharmacology; D014740:Vidarabine / Q000494:pharmacology; D016047:Zalcitabine
D000998:Antiviral Agents; D003839:Deoxyadenosines; D003853:Deoxyribonucleosides; D015224:Dideoxynucleosides; D015683:Gene Products, gag; D008934:Mitogens; D012191:Retroviridae Proteins; D003841:Deoxycytidine; C019336:2',3'-dideoxythymidine; C048407:2',3',5'-trideoxyadenosine; D016048:Dideoxyadenosine; D016047:Zalcitabine; D014740:Vidarabine; D013936:Thymidine